Latest ASX Announcements

Powerful Trial Design to Lead Next Stage DMX-200 Chronic Kidney Disease Subgroup Studies


• Dimerix to launch next stage of lead program, DMX-200, with two simultaneous Phase 2 clinical trials in the area of Chronic Kidney Disease

• Leading global contract research organisation IQVIA has been engaged; 11 Australian trial sites identified

• Recruitment expected to begin in Q3 calendar 2018

MELBOURNE, Australia, 15 May 2018: Dimerix Limited (ASX: DXB), a […]

By | 2018-05-15T07:14:36+00:00 May 15th, 2018|Latest ASX Announcements|

ASX: Lead investigator engaged for DMX-200 Phase 2 trials

Dimerix is pleased to announce that Professor Simon Roger, Director of Renal Research in Gosford, New South Wales, will serve as Principal Investigator for the Company’s coming DMX-200 Phase 2 clinical efficacy trials. Professor David Power, Head of Nephrology at Austin Health in Victoria will lead public hospital involvement, continuing on from his Principal Investigator role […]

By | 2018-05-07T14:55:31+00:00 May 7th, 2018|Latest ASX Announcements|

ASX announcement: Dimerix raises a further A$4.5M

Dimerix Limited  has raised an additional $4.5 million through the issue of 37,500,000 shares at 12 cents per share to wholesale and institutional clients of Westar Capital and Baker Young Stockbrokers who acted as Joint Lead managers to the Issue.

  • Dimerix raises a further A$4.5 million via a significantly oversubscribed Placement.
  • The Capital Raising was […]
By | 2018-02-21T07:01:16+00:00 February 21st, 2018|Latest ASX Announcements|